Interest in developing nasal vaccines to protect against COVID-19 dates back to the early months of the pandemic. Because SARS-CoV-2 first takes hold in the nose, mouth, throat, and lungs, vaccines that target those mucous membranes could be more effective at stopping infection and transmission than injected vaccines. The idea is to stop SARS-CoV-2 sooner by providing protection at the site of infection.

Work on nasal vaccines has resulted in approved products in China and India, both of which use modified adenoviruses to protect against COVID-19, but the global market remains dominated by mRNA vaccines that are injected into the muscles. However, some groups continue to work on nasal vaccines.

Writing in Nature Microbiology, researchers at three German institutes -- Freie Universität Berlin, Max Delbrück Center and Charité – Universitätsmedizin Berlin -- present data on a live nasal vaccine. To make the vaccine, the scientists altered the genetic code of SARS-CoV-2 to weaken the virus and formulated it into a nasally delivered solution. The changes are designed to stop the virus from harming patients.

Administration of the candidate to hamsters suggests the live attenuated nasal vaccine may have some advantages over prophylactic injections based on mRNA. Two doses of the nasal vaccine stopped the virus from replicating in hamsters, whereas animals that received two shots of mRNA suffered damage to the upper tissue layers in the nasal mucosa.

The effectiveness of two doses of the nasal vaccine was underpinned by its effect on the memory T cells that reside in lung tissue, as Geraldine Nouailles, an immunologist and research group leader at Charité, explained in a statement.

"These white blood cells remain in affected tissue long after an infection has passed and remember pathogens they have encountered before. Thanks to their location in the lungs, they can respond quickly to viruses that enter through the airways. We were able to show that prior intranasal vaccination results in the increased reactivation of these local memory cells in the event of a subsequent SARS-CoV-2 infection," Nouailles, the co-first author of the study, said.

The researchers are collaborating with the Swiss startup RocketVax in preparing to test the nasal vaccine in humans. RocketVax plans to rapidly scale up production and advance clinical development in the belief that the delivery technology has great potential in the market for seasonal vaccines.

Pandemic played out in vastly different ways across the U.S.: Study
A comprehensive state-by-state analysis of COVID-19 impacts across the U.S. revealed the underlying forces driving wide variations in health, education,...

COVID-19 vaccine development: Public funding yielded private profits
Decades before the COVID-19 pandemic, the U.S. government invested at least $337 million into critical research that led to mRNA COVID-19 vaccines. The...

Agilent launches cell analysis workflow automation for immuno-oncology, virology, and vaccine development
Agilent Technologies on Friday announced that it has integrated its xCelligence RTCA HT (real-time cell analysis high-throughput) platform with the firm’s...

Vaccine effectiveness against Omicron variants may change over time
Researchers from The Chinese University of Hong Kong and the Harvard T.H. Chan School of Public Health in Boston, Massachusetts collaborated on a case-control...

Study suggests immune response to anticancer checkpoint inhibitors unaffected by COVID-19 vaccination
Immune checkpoint inhibitors perform comparably in vaccinated and unvaccinated individuals, allaying concerns that injections given to protect against...